Physicians' Academy for Cardiovascular Education

DOACs associated with lower risk of liver injury hospitalisation compared to warfarin

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

Alonso A, MacLehose RF, Chen LY et al. - Heart. 2017 Jan 5, doi:10.1136/heartjnl-2016-310586


Although the efficacy of direct oral anticoagulants (DOACs) have been widely studied [1-3], still concerns exist about adverse effects and safety, particularly for less frequent outcomes. For example, an earlier direct thrombin inhibitor (ximelagatran) had been withdrawn from the market after reports of hepatotoxicity emerged. Moreover, recently isolated cases of liver injury associated with the use of dabigatran and rivaroxaban have been published [4,5].

This study investigated the risk of hospitalisation with liver injury after initiation of oral anticoagulantia in 113 717 patients with atrial fibrillation (AF) using data from the large ‘Truven Health MarketScan Commercial Claims and Encounter Database’ and the ‘Medicare Supplemental and Coordination of Benefits Database’ in the USA. Furthermore, predictors of liver injury hospitalisation were studied and a liver injury risk calculator had been developed to help flag patients at higher risk of the complication. 50% of patients were on warfarin, 27% on rivaroxaban, 15% on dabigatran and 8% on apixaban.

Main results


Although literature describes isolated case reports of hepatotoxicity linked to DOACs, the risk of liver injury hospitalisation among patients starting DOACs was lower than those starting warfarin. Among DOACs, risk was highest for rivaroxaban users compared with dabigatran and apixaban users. Moreover, several patient characteristics were predictive for liver injury hospitalisation which were used in an excel-based calculator that can help clinicians deciding between anticoagulants.


Show references

Find this publication online at Heart